Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab vs Secukinumab in Moderate to Severe Plaque Psoriasis
2017-004932-12Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of risankizumab in plaque psoriasis and psoriasis (2 arms), sponsored by AbbVie Inc. Started Jun 2018; status: completed.
02
Drugs
risankizumab
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2017-004932-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004932-12.